Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Targeting Nrf2 may reverse the drug resistance in ovarian cancer

Fig. 2

The classical view of Nrf2 activation and response. Under physiological conditions, Nrf2 is anchored in the cytoplasm by Keap1 as a substrate for Cullin 3-dependent E3 ubiquitin ligase complex and can induce ubiquitination and promptly degrade Nrf2 via the proteasome. However, when ROS or electrophiles attack cells, Nrf2 detaches from Keap1 and is rapidly transferred into the nucleus, forming a heterodimer with the sMaf protein and then integrating with the ARE, thereby transcriptionally activating Nrf2-regulated antioxidant gene expression including HO-1,NQO1,GCL,PRDX and SOD to exert anti-oxidative effects

Back to article page